ClinicalTrials.Veeva

Menu

Endoscopic Ultrasound Plus Submucosal Injection for Early Esophageal Cancer

Sun Yat-sen University logo

Sun Yat-sen University

Status

Unknown

Conditions

Esophageal Cancer

Treatments

Device: submucosal injection needle ; EUS
Device: ordinary endosonography(EUS)

Study type

Interventional

Funder types

Other

Identifiers

NCT01555801
1122
112273

Details and patient eligibility

About

Preoperative accurately staging T1a or T1b in early esophageal cancer is vital for the choices of treatment. At present, the main diagnostic method for early esophageal cancer is endoscopic ultrasound (EUS). However, the accuracy of EUS alone is poor. Thus, it is necessary to improve endoscopic ultrasound examination methods. This project is concerning on the efficacy of EUS combining with submucosal injection of saline for staging T1a and T1b-esophageal cancer. Patients and methods: 80 cases of pathological confirmed early esophageal cancer were randomly divided into two groups: endoscopic ultrasonography group (EUS group) and EUS combining with submucosal injecting saline group (EUS+SIS group). All the cases will be performance by endoscopic or surgical resection; postoperative pathologic diagnosis will be obtained involving echo, depth, margin and other features. The EUS results of two groups of patients will be compared with pathologic results. From comparison, the efficacy and accuracy of EUS+SIS for staging T1a and T1b in esophageal cancer patients will be validated. Through this study, the investigators may develop a routine diagnostic and accurately staging method for early esophageal cancer patients.

Full description

Someone whom may concern our IPD are available to the PI, Jian-jun Li M.D. or at lijj@sysucc.org.cn

Enrollment

80 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age 18-65 years old, no gender limited;
  • Patients with esophageal squamous cell carcinoma who be confirmed by ordinary endoscopy and pathologic biopsy;
  • Patients who agree to accept endoscopic resection or surgical excision of the lesion in esophagus;
  • patients with normal cardio-pulmonary function and normal coagulative function,are predicted to be tolerated anesthesia and surgery;
  • patients who understand test purpose, volunteer to join these study and sign the consent inform.

Exclusion criteria

  • Patients with stages of T2, T3, or T4 displayed by EUS;
  • Patients who can't tolerate endoscopy and surgical treatment for various reasons;
  • Patients who have distant metastasis, or multiple source of malignant tumors;
  • Patients with blood coagulative disorder;
  • Patients don't accept the endoscopic examination or surgical treatment;
  • Patients with poor compliancy.

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

80 participants in 2 patient groups, including a placebo group

Submucosal injection combining with EUS
Experimental group
Description:
The enrolled patients will be accepted submucosal injection of saline,then ultrasonography will performed(EUS+SIS group).So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) or endoscopic submucosal dissection(ESD) or esophagectomy.
Treatment:
Device: submucosal injection needle ; EUS
ordinary endosonography(EUS)
Placebo Comparator group
Description:
The enrolled patients will accept ordinary ultrasonography .So,stages of EUS in these early esophageal cancer will be recorded and compared with the pathological stages afer endoscopic mucosal resection(EMR) , endoscopic submucosal dissection(ESD) or esophagectomy.
Treatment:
Device: ordinary endosonography(EUS)

Trial contacts and locations

1

Loading...

Central trial contact

Jian-jun Li, M.D. Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems